Cyclerion Therapeutics IncNASDAQ:CYCN
- LAST PRICE2.9000
- TODAY'S CHANGE (%)-0.0099 (-0.3402%)
- Bid / Lots2.8000/ 6
- Ask / Lots2.9200/ 1
- Open / Previous Close2.9900 / 2.9099
- Day Range
- 52 Week Range
- Volume5,372
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CYCN |
|---|---|---|
| 09:32 ET | 612 | 3.04 |
| 09:52 ET | 2931 | 2.894 |
| 09:59 ET | 300 | 2.89 |
| 10:06 ET | 100 | 2.83 |
| 10:28 ET | 300 | 2.8247 |
| 10:37 ET | 200 | 2.8289 |
| 10:53 ET | 100 | 2.86 |
| 11:06 ET | 147 | 2.91 |
| 11:11 ET | 100 | 2.9 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cyclerion Therapeutics Inc | 7.9M | -0.7x | --- |
Alzamend Neuro Inc | 7.7M | -0.2x | --- |
Purple Biotech Ltd | 7.7M | 0.0x | --- |
Moleculin Biotech Inc | 7.6M | -0.2x | --- |
Virpax Pharmaceuticals Inc | 8.5M | 0.0x | --- |
Check Cap Ltd | 8.5M | -0.5x | --- |
Company Information
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Contact Information
- Headquarters
- 301 Binney StreetCAMBRIDGE, MA, United States 02142
- Phone
- 617-621-7722
- Fax
- ---
Executives
- Independent Chairman of the Board
- Errol De Souza
- President, Chief Executive Officer, Director
- Regina Graul
- Chief Financial Officer
- Rhonda Chicko
- Director
- Peter Hecht
- Independent Director
- Michael Higgins
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.95 |
EPS | $-4.26 |
Book Value | $4.56 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
